» Articles » PMID: 32387230

When Fear and Misinformation Go Viral: Pharmacists' Role in Deterring Medication Misinformation During the 'infodemic' Surrounding COVID-19

Overview
Publisher Elsevier
Specialty Pharmacy
Date 2020 May 11
PMID 32387230
Citations 79
Authors
Affiliations
Soon will be listed here.
Abstract

The world has faced an unprecedented challenge when coronavirus (COVID-19) emerged as a pandemic. Millions of people have contracted the virus and a significant number of them lost their lives, resulting in a tremendous social and economic shock across the globe. Amid the growing burden of the pandemic, there are parallel emergencies that need to be simultaneously tackled: the proliferation of fake medicines, fake news and medication misinformation surrounding COVID-19. Pharmacists are key health professionals with the required skills and training to contribute to the fight against these emergencies. Primarily, they can be a relevant source of accurate and reliable information to the public or other fellow health professionals thereby reducing the spread of COVID-19 medication misinformation. This can be achieved by providing accurate and reliable information based on recommendations given by relevant health authorities and professional associations to make sure the community understand the importance of the message and thus minimise the detrimental consequences of the pandemic. This commentary aims to summarise the existing literature in relation to the promising treatments currently under trial, the perils of falsified medications and medicine-related information and the role of pharmacists in taking a leading role in combating these parallel global emergencies.

Citing Articles

A Critical Juncture for Drug Information and Evidence-Based Voices.

Kier K J Pediatr Pharmacol Ther. 2025; 30(1):143-145.

PMID: 39935562 PMC: 11809542. DOI: 10.5863/1551-6776-30.1.143.


Patient-centric decision-making in supplements intake and disclosure in clinical practice: a novel SIDP-12 tool to prevent drug-supplement interaction.

Ait Gacem S, Huri H, Wahab I, Abduelkarem A Ther Adv Drug Saf. 2024; 15:20420986241294150.

PMID: 39483421 PMC: 11526152. DOI: 10.1177/20420986241294150.


Evaluation of Drug and Herbal Medicinal Promotions on Social Media During the COVID-19 Pandemic in Relation to World Health Organization Ethical Criteria and South African Health Products Regulatory Authority Guidelines in South Africa:....

Chimukuche R, Ndlazi J, Mtolo L, Bird K, Seeley J Online J Public Health Inform. 2024; 16:e58378.

PMID: 39293046 PMC: 11447434. DOI: 10.2196/58378.


Insights from the EQUALS4COVID19 study on migrant mental health in Portugal: a cross-sectional mixed-methods approach.

Alarcao V, Candeias P, Stefanovska-Petkovska M, Neves J, Pintassilgo S, Machado F BMC Public Health. 2024; 24(1):2023.

PMID: 39075428 PMC: 11285180. DOI: 10.1186/s12889-024-19563-x.


Beliefs about COVID-19 testing and treatment: A national survey of Black and White adults.

Siminoff L, Barker K, Blunt R, Litsas D, Alolod G, Patel J Public Health Pract (Oxf). 2024; 8:100519.

PMID: 39027346 PMC: 11255099. DOI: 10.1016/j.puhip.2024.100519.


References
1.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H . Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020; 81(1):e1-e5. PMC: 7156152. DOI: 10.1016/j.jinf.2020.03.002. View

2.
Gautret P, Lagier J, Parola P, Hoang V, Meddeb L, Sevestre J . Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34:101663. PMC: 7151271. DOI: 10.1016/j.tmaid.2020.101663. View

3.
Lythgoe M, Middleton P . Ongoing Clinical Trials for the Management of the COVID-19 Pandemic. Trends Pharmacol Sci. 2020; 41(6):363-382. PMC: 7144665. DOI: 10.1016/j.tips.2020.03.006. View

4.
Li C, Zu S, Deng Y, Li D, Parvatiyar K, Quanquin N . Azithromycin Protects against Zika virus Infection by Upregulating virus-induced Type I and III Interferon Responses. Antimicrob Agents Chemother. 2019; 63(12). PMC: 6879226. DOI: 10.1128/AAC.00394-19. View

5.
Ling Hu , Chen S, Fu Y, Gao Z, Long H, Ren H . Risk Factors Associated With Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China. Clin Infect Dis. 2020; 71(16):2089-2098. PMC: 7197620. DOI: 10.1093/cid/ciaa539. View